Depakote bottles used to treat epilepsy and bipolar disorder are being pulled from pharmacies across the country after reports that some containers may hold stray pills that do not belong there. The voluntary recall targets Bionpharma's 500 mg delayed-release divalproex sodium tablets in 500-count bottles and has triggered alerts from pharmacy boards and health reporters. Patients on valproate products are being urged not to abruptly stop their medicine and instead to contact their prescriber or pharmacist if they think they may have an affected bottle.
What was recalled
The recall specifically covers Divalproex Sodium Delayed-Release Tablets, USP, 500 mg, packaged in 500-tablet bottles (NDC 69452-435-30) distributed by Bionpharma Inc. The official label and prescribing information list Bionpharma of Princeton, N.J., and are posted on DailyMed so pharmacies and clinicians can cross-check what is sitting on their shelves.
Why it was recalled
State pharmacy notices report that reserve samples turned up foreign tablets or capsules, indicating a packaging or manufacturing error that may have caused cross-contamination. The recall was initiated on June 26, 2026, and state boards began adding the event to their public alerts in early July. Coverage noted that the FDA Enforcement Report had not yet assigned a formal classification when the recall first appeared, according to PIX11. Public notices list the recalled product as distributed from Princeton, N.J., and highlight the packaging issue on state recall pages such as the California State Board of Pharmacy.
What patients should do
If you or someone in your household takes divalproex, start by checking the NDC and any lot information on your bottle against the recall details your pharmacy provides, then call your pharmacist to confirm whether your specific bottle is affected. Do not stop divalproex suddenly, since the drug labeling warns that abrupt cessation can trigger seizures. Instead, reach out to your prescriber before making any changes and follow their instructions. You can report any adverse reactions to the FDA's MedWatch program, and the manufacturer lists consumer contact information on the product label for questions and returns, with more details available on the FDA MedWatch page and in the product labeling.
Regulatory context
Divalproex products have been subject to recalls before, for issues that have included failed dissolution and cross-contamination, and the FDA tracks these events through its Enforcement Report while state boards push alerts to pharmacies. Recall trackers and aggregators are listing the current Bionpharma recall as one that is being monitored across pharmacy networks as regulators complete their hazard assessment. Consumers are being told to check official recall pages and to work with their pharmacy for lot-by-lot details, including the NDC 69452-435-30 packaging entry that appears on NDC registries.
If your bottle matches the recalled packaging or listed lot numbers, your pharmacist can verify the product and arrange a return or replacement as needed. For any concerning symptoms after taking a medication, contact a clinician promptly and file a report with FDA MedWatch.
